Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

Dana-Farber Cancer Institute

Status: Completed

Conditions: CNS Lymphoma; CNS Involvement of Systemic Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01319591

11-043

Details and patient eligibility

About

The purpose of this study is to compare different estimates of calculating creatinine clearance by mathematical formula and compare them to creatinine clearance based on a timed urine collection in patients who received high-dose methotrexate for the treatment of primary CNS lymphoma or CNS involvement of systemic lymphoma.

Full description

We intend to perform a retrospective chart review to identify a serum creatinine-based equation that gives the best estimate of CrCl as compared with an equation derived from a 24-hour urine collection.

Study subjects will be identified using the Brigham and Women's Hospital and Dana-Farber Cancer Institute's Adult Pharmacy systems to identify patients who received high-dose methotrexate. Data will be collected starting with December 31, 2010 and proceeding chronologically backwards until the target enrollment of 40 patients is reached.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >/= 18 years
• Received high-dose methotrexate therapy at Dana-Farber Cancer Institute/Brigham and Women's Hospital for the treatment of primary CNS lymphoma or CNS involvement of systemic lymphoma
• Available timed urine collection within 1 week of HDMTX

Exclusion criteria

• Receiving high-dose methotrexate for indications other than primary CNS lymphoma or CNS involvement of systemic lymphoma
• Documented viral hepatitis

Trial design

40 participants in 1 patient group

CNS lymphoma patients